COMMUNIQUÉS West-GlobeNewswire

Tonix Pharmaceuticals to Present at Upcoming Investor Conferences
25/03/2019
NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at two upcoming investor conferences. Details [...]
Soleno Therapeutics to Participate in the ROTH Battle of NASH Thrones Spring Investor Conference
25/03/2019
REDWOOD CITY, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
VBL Therapeutics to Present at Upcoming Conferences in April
25/03/2019
TEL AVIV, Israel, March 25, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announces that the Company will present data on its Phase 3 drug candidate VB-111, at the 2019 American Association for Cancer [...]
BeyondSpring Advancing Patient Targeting Strategies for Lead Asset Plinabulin
25/03/2019
Newly Discovered Predictive Algorithms to be Presented at 2019 American Association for Cancer Research Annual Meeting NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global [...]
Strongbridge Biopharma plc Announces Presentation of New Data Analyses from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome
25/03/2019
~ Subgroup Analysis of Patients with Comorbid Diabetes Mellitus and Cushing’s Syndrome Presented at Annual Meeting of the Endocrine Society (ENDO) Shows Potential Clinical Benefit of Treatment with RECORLEV™ ( [...]
OpGen and Merck’s ILÚM Health Solutions to Host Event at VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship
25/03/2019
GAITHERSBURG, Md., March 25, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc . (Nasdaq: OPGN) announced today it will host an event with ILÚM Health Solutions, LLC (“ILÚM”), a wholly owned subsidiary of Merck’s Healthcare Services [...]
Radient Technologies Inc. Announces Addition of Three Key Members to its Management Team
25/03/2019
EDMONTON, Alberta, March 25, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI; OTCQX: RDDTF ) is pleased to announce that it has appointed Mr. Adrian Marshall and Mr. [...]
Neutral Connect Networks Acquires Connectivity Wireless Solutions Extending its Leadership in the Growing Neutral-Host Infrastructure and Services Business
25/03/2019
BOSTON, March 25, 2019 (GLOBE NEWSWIRE) -- Neutral Connect Networks announced today the acquisition of Connectivity Wireless Solutions by M/C Partners, a Boston-based private equity firm which is the leading equity [...]
Translate Bio to Participate in Upcoming Investor Conferences
25/03/2019
LEXINGTON, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat [...]
Onconova Achieves Over 75 Percent of Planned Enrollment in Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes
25/03/2019
Full enrollment of 360 patients anticipated in second half of 2019 Pivotal global study continues enrolling worldwide Potential for first new therapy in 15 years to address unmet medical need in MDS NEWTOWN, Pa., March [...]
Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program
25/03/2019
CAMBRIDGE, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it will host a webcast and conference call at 8: [...]
Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806
25/03/2019
– CG-806 highly potent, oral, non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – Phase 1 trial in relapsed or refractory CLL and B cell [...]
Notice of Results
25/03/2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019 Oxford, UK, and Cambridge, MA, US, 25 March 2019 [...]
Iterum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
25/03/2019
--On Track to Complete its Three Phase 3 Clinical Trials in 2019 -- --Received Qualified Infectious Disease Product Designation in Four Additional Indications-- --Fast Track Designation received from the FDA in seven [...]
MediWound Reports Fourth Quarter and Fiscal Year 2018 Financial Results
25/03/2019
Met Primary and All Secondary Endpoints in its Pivotal Phase 3 Study (DETECT) in NexoBrid ® for Eschar Removal of Severe Thermal Burns Awarded Additional BARDA Contract Valued up to $43 Million for the Development of [...]
Arvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC™ Protein Degrader, ARV-110
25/03/2019
Study to Evaluate Safety and Tolerability of Androgen Receptor (AR)-targeted PROTAC™ Protein Degrader in Patients with Metastatic Castration-Resistant Prostate Cancer NEW HAVEN, Conn., March 25, 2019 (GLOBE NEWSWIRE [...]
Canopy Rivers Portfolio Company Licensed by Health Canada, Triggering Long-Term Cash Flow Stream
25/03/2019
TORONTO, March 25, 2019 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (“ Canopy Rivers ” or the “ Company ”) (TSXV: RIV) congratulates Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (“ Canopy Growth ”) and its portfolio [...]
XORTX Shares Findings of New Diabetes Study Supporting Uric Acid as an Independent Risk Factor
25/03/2019
● An Opportunity to Expand XORTX’s Pipeline under Existing Patents ● CALGARY, Alberta, March 25, 2019 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a [...]
Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor
25/03/2019
-- PALOMA-3 study gene expression profiling shows that CDK2 is a key kinase bypass mechanism after treatment with palbociclib plus hormone therapy -- -- Cyclin E is proposed as the first predictive biomarker of [...]

Pages